HP
MCID: EXT034
MIFTS: 58

Extrinsic Allergic Alveolitis (HP)

Categories: Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Extrinsic Allergic Alveolitis

MalaCards integrated aliases for Extrinsic Allergic Alveolitis:

Name: Extrinsic Allergic Alveolitis 12 58 36 15 17 71
Hypersensitivity Pneumonitis 12 52 58 15 62
Alveolitis, Extrinsic Allergic 74 52 43
Alveolitis 12 54 71
Extrinsic Allergic Pneumonia Hypersensitivity Pneumonitis 52
Allergic Interstitial Pneumonitis 52
Pneumonitis Hypersensitivity 54
Allergic Pneumonitis 52
Hp 52

Characteristics:

Orphanet epidemiological data:

58
hypersensitivity pneumonitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare allergic disease


External Ids:

Disease Ontology 12 DOID:841
KEGG 36 H00346
ICD9CM 34 495
MeSH 43 D000542
NCIt 49 C34369
SNOMED-CT 67 37471005
ICD10 32 J67 J67.8 J67.9
MESH via Orphanet 44 D000542
UMLS via Orphanet 72 C0002390
Orphanet 58 ORPHA31740
UMLS 71 C0002390 C0549493

Summaries for Extrinsic Allergic Alveolitis

KEGG : 36 Extrinsic allergic alveolitis (EAA), also known as hypersensitivity pneumonitis, is caused by repeated inhalation of mainly organic antigens by sensitized subjects. This induces a hypersensitivity response in the distal bronchioles and alveoli and subjects may present clinically with a variety of symptoms. EAA is caused by a wide variety of antigens including bacteria, organic materials, fungal spores, and chemicals. Of the various EAA syndromes, Farmer's lung and Bird fancier's disease are the commonest forms that have been studied. EEA is a complex dynamic clinical syndrome where clinical expression depends on the frequency and amount of contact with antigen and host susceptibility. The manifestations and symptoms can be complicated by self-regulatory measures performed by those affected individuals to reduce antigen exposure. There are many individuals with a positive antibody reaction who remain asymptomatic. EEA traditionally has been described as occurring in a state of acute, subacute, and chronic form.

MalaCards based summary : Extrinsic Allergic Alveolitis, also known as hypersensitivity pneumonitis, is related to bagassosis and pulmonary edema, and has symptoms including hemoptysis An important gene associated with Extrinsic Allergic Alveolitis is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Clavulanate and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 An interstitial lung disease involving inflammation of alveoli and smallest airways (bronchioles) of the lung caused by an allergic reaction to inhaled organic dusts containing microorganisms or proteins, and chemicals. Symptoms include chills, cough, fever, malaise, shortness of breath, loss of appetite and weight loss.

PubMed Health : 62 About hypersensitivity pneumonitis: Hypersensitivity pneumonitis (noo-mo-NI-tis), or HP, is a disease in which the lungs become inflamed from breathing in foreign substances, such as molds, dusts, and chemicals. These substances also are known as antigens (AN-tih-jens). People are exposed to antigens at home, while at work, and in other settings. However, most people who breathe in these substances don't develop HP.

Wikipedia : 74 Hypersensitivity pneumonitis (HP) or extrinsic allergic alveolitis (EAA) is a rare immune system... more...

Related Diseases for Extrinsic Allergic Alveolitis

Diseases related to Extrinsic Allergic Alveolitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 936)
# Related Disease Score Top Affiliating Genes
1 bagassosis 33.2 IL1B CXCL8
2 pulmonary edema 32.8 IL1B IL10 HP CXCL8
3 rheumatic fever 32.7 IL6 IL10 HP ALB
4 sleeping sickness 32.7 IL6 IL10 HP
5 endometritis 32.6 IL6 IL1B HP CXCL8
6 mastitis 32.5 IL6 HP CXCL8 CCL5 ALB
7 plasmodium falciparum malaria 32.5 IL6 IL10 HP ALB
8 pancytopenia 32.4 MPO IL6 IL2RA HP ALB
9 trachoma 32.4 IL6 IL10 HP
10 hellp syndrome 32.4 IL6 IL10 HP CXCL8
11 vascular disease 32.4 MPO IL6 IL10 HP CCL2 ALB
12 urinary schistosomiasis 32.3 IL10 IGHE HP
13 cardiovascular system disease 32.3 MPO IL6 HP CCL2 ALB
14 protein-energy malnutrition 32.2 MPO IL6 HP ALB
15 thrombocytopenia 32.2 IL6 IL1B IL10 HP CXCL8 CCL2
16 reactive arthritis 32.1 MPO IL6 IL1B IL10 HP CXCL8
17 vaginal discharge 32.1 IL6 IL1B HP CXCL8
18 lipoprotein quantitative trait locus 32.1 IL6 IL1B IL10 HP CXCL8 ALB
19 heart disease 32.1 SOD2 IL6 IL1B IL10 HP CXCL8
20 blood coagulation disease 32.0 IL6 IL10 HP ALB
21 intracranial berry aneurysm 32.0 IL6 IL1B HP ALB
22 dysentery 32.0 IL6 IL1B IL10 HP CXCL8 ALB
23 sclerosing cholangitis 32.0 MPO IL6 IL10 HP CXCL8 ALB
24 cholangitis 32.0 MPO IL6 IL10 HP CXCL8 ALB
25 endometrial disease 31.9 IL6 IL1B IL10 HP CXCL8
26 autoimmune disease of blood 31.9 MPO IL6 IL10 HP ALB
27 crohn's disease 31.8 IL6 IL1B IL10 HP CXCL8 CCL2
28 chronic kidney disease 31.7 MPO IL6 IL1B IL10 HP CCL2
29 hypertension, essential 31.6 SOD2 MPO IL6 IL1B IL10 HP
30 autoimmune disease of gastrointestinal tract 31.6 IL6 IL1B IL15 IL10 HP ALB
31 bronchopneumonia 31.5 PI3 MPO IL6 IL1B IL10 HP
32 cystic fibrosis 31.4 SFTPD PI3 MPO IL6 IL1B IL10
33 tropical spastic paraparesis 31.4 IL6 IL2RA IL15 IL10 CXCR3 CCL5
34 trypanosomiasis 31.3 IL6 IL1B IL10 HP CXCR3 CXCL8
35 helicobacter pylori infection 31.3 IL1B CXCL8 CCL5
36 diabetes mellitus 31.3 SOD2 MPO IL6 IL2RA IL1B IL10
37 systemic scleroderma 31.3 SFTPD IL6 IL1B IL10
38 allergic hypersensitivity disease 31.3 SFTPD IL10 IGHE FCER2 CXCL8 CCL5
39 gastric ulcer 31.2 IL6 IL1B CXCL8
40 blood platelet disease 31.2 IL6 HP ALB
41 parasitic protozoa infectious disease 31.2 IL6 IL1B IL10 HP CXCL8 CCL3
42 peptic ulcer disease 31.2 IL1B IL10 CXCL8 ALB
43 duodenal ulcer 31.1 IL6 IL1B IL10 CXCL8
44 atrophic gastritis 31.1 IL6 IL1B IL10 CXCL8
45 asbestosis 31.1 SOD2 MPO IL6 IL1B
46 allergic bronchopulmonary aspergillosis 31.1 SFTPD IL10 IGHE
47 respiratory syncytial virus infectious disease 31.0 CCL5 CCL3
48 ulcerative colitis 31.0 MPO IL6 IL1B IL10 CXCL8
49 hypersensitivity vasculitis 31.0 MPO IL6 ALB
50 gastritis 31.0 IL6 IL1B IL10 CXCL8 CXCL5 CCL5

Comorbidity relations with Extrinsic Allergic Alveolitis via Phenotypic Disease Network (PDN):


Heart Disease Postinflammatory Pulmonary Fibrosis

Graphical network of the top 20 diseases related to Extrinsic Allergic Alveolitis:



Diseases related to Extrinsic Allergic Alveolitis

Symptoms & Phenotypes for Extrinsic Allergic Alveolitis

UMLS symptoms related to Extrinsic Allergic Alveolitis:


hemoptysis

GenomeRNAi Phenotypes related to Extrinsic Allergic Alveolitis according to GeneCards Suite gene sharing:

26 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.85 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.85 CXCR3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.85 CCL5
4 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.85 CXCL2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-112 9.85 CCL5
6 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.85 IL10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.85 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.85 CXCR3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.85 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.85 CXCL2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.85 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.85 CXCL2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.85 CXCR3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.85 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.85 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.85 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.85 CCL5
18 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.85 CCL5 IL10
19 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.85 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.85 CXCL2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.85 CCL5 CXCL2 CXCR3 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.85 IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.85 CXCL2 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-71 9.85 CXCL2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.85 CXCL2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.85 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.85 CCL5
28 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.85 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.85 CXCR3

MGI Mouse Phenotypes related to Extrinsic Allergic Alveolitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10 ALB CXCL2 CXCR3 HP IL10 IL15
2 hematopoietic system MP:0005397 9.93 CCL5 CXCR3 FCER2 HP IL10 IL15
3 immune system MP:0005387 9.8 ALB CCL2 CCL5 CXCR3 FCER2 HP
4 neoplasm MP:0002006 9.17 ALB CXCR3 HP IL10 IL1B IL6

Drugs & Therapeutics for Extrinsic Allergic Alveolitis

PubMed Health treatment related to Extrinsic Allergic Alveolitis: 62

The best way to treat hypersensitivity pneumonitis (HP) is to avoid the antigen that caused it. (An antigen is a substance that your body reacts against, such as molds , dusts, and chemicals.) In acute (short-term) HP, symptoms usually go away once you're no longer in contact with the antigen . In chronic (ongoing) HP, you may need medicines to relieve your symptoms. People who have chronic HP may develop pulmonary fibrosis . This is a condition in which tissue deep in your lungs becomes scarred over time. People who have this condition may need further treatment , such as oxygen therapy and pulmonary rehabilitation (rehab).

Drugs for Extrinsic Allergic Alveolitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
2
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
3
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
4
Ethanol Approved Phase 4 64-17-5 702
5 Anti-Bacterial Agents Phase 4
6 Antibiotics, Antitubercular Phase 4
7 Sulfalene Phase 4
8 Amoxicillin-Potassium Clavulanate Combination Phase 4
9 Lactoferrin Phase 4
10 beta-Lactamase Inhibitors Phase 4
11 Bifidobacterium Phase 4
12 Disinfectants Phase 4
13 Anti-Infective Agents, Local Phase 4
14 Chlorhexidine gluconate Phase 4
15 Anti-Infective Agents Phase 4
16
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
17
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
18
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
19
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
20 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
21
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
22
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
23
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
24
Bosentan Approved, Investigational Phase 2, Phase 3 147536-97-8 104865
25
Lenograstim Approved, Investigational Phase 3 135968-09-1
26
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
27
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
28
leucovorin Approved Phase 3 58-05-9 6006 143
29
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
31
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
32 Methylprednisolone Acetate Phase 3
33 Anti-Inflammatory Agents Phase 3
34 Antirheumatic Agents Phase 3
35 Hormones Phase 3
36 Antineoplastic Agents, Hormonal Phase 3
37 glucocorticoids Phase 3
38 Hormone Antagonists Phase 3
39 Antihypertensive Agents Phase 2, Phase 3
40 Endothelin Receptor Antagonists Phase 2, Phase 3
41 Phosphodiesterase 5 Inhibitors Phase 3
42 Phosphodiesterase Inhibitors Phase 3
43 Vasodilator Agents Phase 3
44 Immunologic Factors Phase 3
45 Alkylating Agents Phase 3
46 Immunosuppressive Agents Phase 3
47 Vitamin B Complex Phase 3
48 Folic Acid Antagonists Phase 3
49 Folate Phase 3
50 Dermatologic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Antibiotic Therapy in Erupted Tooth Extractions Completed NCT04082598 Phase 4 Amoxicillin Clavulanate
2 Comparing the Effect of Oral Methyl Prednisolone on Different Radiological Patterns of Hypersensitivity Pneumonitis Recruiting NCT04402177 Phase 4 Methyl Prednisolonate
3 Examination of the Prevention and Treatment Modalities of Alveolitis in Relation With Impacted Teeth Surgery Recruiting NCT03741894 Phase 4 Iodoform;Chlorhexidine
4 Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment Unknown status NCT02496182 Phase 2, Phase 3 Placebo;Pirfenidone;Pirfenidone
5 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis Completed NCT00070590 Phase 2, Phase 3 Bosentan
6 Cyclophosphamide Versus Placebo in Scleroderma Lung Study Completed NCT00004563 Phase 3 Cyclophosphamide;Placebo
7 High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma) Completed NCT00501995 Phase 3 IV Cyclophosphamide
8 A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
9 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
10 Low-Dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: A Phase II Pilot Study Unknown status NCT00573326 Phase 2 Imatinib
11 Pilot Study to Examine The Use of Imatinib (Gleevec) For The Treatment of Active Alveolitis in Systemic Sclerosis Completed NCT00512902 Phase 1, Phase 2 Imatinib;Imatinib
12 Vasodilator Therapy and Exercise Tolerance in IPF Patients Completed NCT00359736 Phase 2 sildenafil
13 Trial of High Dose Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG) With Hematopoietic Stem Cell Support in Patients With Systemic Scleroderma: A Randomized Trial Completed NCT00278525 Phase 2 standard of care
14 Effect of Sildenafil on Digital Ulcers in Systemic Sclerosis Completed NCT00624273 Phase 2 Sildenafil therapy
15 Multi-centre, Open-label, First-in-man Study of Adult Patients Suffered From Alveolar Osteitis Treated Using Stomatological Tamponade Contipro Completed NCT04091399 Phase 2 Stamatological tamponade Contipro
16 Highdose Chemotherapy and Transplantation of 34+ Selected Stem Cell for Progressive Systemic Sclerosis - Modification According to Manifestation Recruiting NCT01895244 Phase 2 Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
17 Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma Recruiting NCT03313323 Phase 2
18 Stop Exogenous Allergic Alveolitis (EAA) in Childhood: Healthy Into Adulthood - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prednisolone Treatment and Course of Disease Suspended NCT02631603 Phase 2 Placebo;Prednisolone
19 A Double Blind, Controlled by Conventional BCG, Dose-escalation Phase I Study, to Evaluate Safety, Tolerability and Immunogenicity of a Mycobacterium Bovis BCG (Bacillus Calmette-Guérin) Vaccine, 1331 Danish Strain, Live Attenuated and Recombinant for the Expression of Human Respiratory Syncytial Virus Nucleoprotein (N) in Healthy Males Within 18 and 50 Years of Age Unknown status NCT03213405 Phase 1
20 A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis Completed NCT00563212 Phase 1 aerosol interferon-gamma
21 The Role of JAK2 in Alveolar Macrophages in Chronic Beryllium Disease Unknown status NCT02596347
22 The Role of Fibrocytes in Acute Lung Injury Unknown status NCT01373203
23 Definition of the Status of the Human Lung Stem Cell Niches ex Vivo in Tissue Biopsies Performed in Patients With Emphysema and Interstitial Fibrosis Compared to Non-diseased Areas Unknown status NCT02705144
24 Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: a Randomized, Double-Blind, Controlled Study Unknown status NCT00518310 Placebo;AZAPRED
25 Wound Healing After Tooth Extraction in Individuals With Type 1 Diabetes Mellitus Unknown status NCT02953249
26 Study to Determine the Immune Response From Broncho-alveolar Cells Against Pigeon Specific Antigens Completed NCT01237145
27 Study of Wind Reed Instruments' Fungal Contamination and Its Immunological and Clinical Consequences for Musicians. Completed NCT01487850
28 Research for Specific Proteins of Interest for the Serological Diagnosis of Bird Fancier's Lung Completed NCT03056404
29 Evaluation of Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis and Its Impact on Exercise Limitation Completed NCT02523833 Salbutamol
30 Observing the Effects of Supplemental Oxygen on Patients With Pulmonary Fibrosis Completed NCT01961362
31 Work-related Respiratory Symptoms in Champagne Vineyard Workers Completed NCT02883920
32 Pulmonary Involvement in Scleroderma: Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients Completed NCT00333437 Mycophenolate mofetil
33 Pilot Investigation on the Combined Use of Established Clinical Criteria and Systems Biology for Progressive Pulmonary Fibrosis Completed NCT01687946
34 Effect of Highly Active Antiretroviral Therapy (HAART) on Viral Burden and Immune Function in the Lungs of HIV-Infected Subjects Completed NCT00001110
35 Pulsed Electromagnetic Fields for Postoperative Pain: a Randomized Controlled Clinical Trial in Patients Undergoing Mandibular Third Molar Extraction Completed NCT02273999
36 Pulmonary Fibrosis Contact Registry Completed NCT01935726
37 Study of the Effects of Bronchoalveolar Lavage Liquid in the ARDS on the Functioning of the Neutrophil Polynuclear System Completed NCT04008225
38 Predictors of Mortality in Patients With Advanced Lung Disease in Home Oxygen Therapy Completed NCT02571582
39 Clinical Utility of Fibered Confocal Fluorescence Microscopy Imaging in Patients With Diffuse Parenchymal Lung Diseases Completed NCT01624753
40 Effect of Probiotic Intervention With Lactobacillus Brevis KABP052 (CECT7480) and Lactobacillus Plantarum KABP051 (CECT7481) After Surgical Removal of Mandibular Third Molars: a Randomized, Controlled, Double-blinded Trial Completed NCT04203771 Ibuprofen
41 Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases Completed NCT00005317
42 A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) Completed NCT00005276
43 A Prospective Study Measuring Exhaled Nitric Oxide in Exercise-Induced Asthma Completed NCT01097954
44 British Pigeon Fanciers Genetics of Interstitial Lung Disease Study Recruiting NCT03747627
45 CD4 T-cell Immunephenotype in Hypersensitivity Pneumonitis Recruiting NCT03873649
46 Toward a Model of Self-management; Identifying Gaps and Needs in Services for Patients With Interstitial Lung Disease Recruiting NCT03300583
47 Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis Recruiting NCT03268330
48 The Effectiveness of an Empirical Chinese Medicine Formulation for Idiopathic Pulmonary Fibrosis: an Open Label Clinical Trial Recruiting NCT03274544
49 A Randomized, Double-Blind, Placebo-Controlled, Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis Active, not recruiting NCT02958917 Pirfenidone
50 Recognition of Pulmonary Hypertension in Patients With Hypersensitivity Pneumonitis Enrolling by invitation NCT03030807

Search NIH Clinical Center for Extrinsic Allergic Alveolitis

Cochrane evidence based reviews: alveolitis, extrinsic allergic

Genetic Tests for Extrinsic Allergic Alveolitis

Anatomical Context for Extrinsic Allergic Alveolitis

MalaCards organs/tissues related to Extrinsic Allergic Alveolitis:

40
Lung, T Cells, Testes, Neutrophil, Monocytes, Skeletal Muscle, Skin

Publications for Extrinsic Allergic Alveolitis

Articles related to Extrinsic Allergic Alveolitis:

(show top 50) (show all 2950)
# Title Authors PMID Year
1
Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases. 61 54
19117745 2009
2
Interleukin 12, interleukin 18, and tumor necrosis factor alpha release by alveolar macrophages: acute and chronic hypersensitivity pneumonitis. 54 61
19230467 2009
3
Upregulation of Th1 cytokine profile in bronchoalveolar lavage fluid of patients with hypersensitivity pneumonitis. 54 61
19218674 2008
4
Immunohistochemical distribution of SP-D, compared with that of SP-A and KL-6, in interstitial pneumonias. 54 61
17874049 2007
5
Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. 61 54
16837501 2006
6
Involvement of eicosanoids and surfactant protein D in extrinsic allergic alveolitis. 54 61
16319337 2005
7
Production of IL-12, IL-18 and TNF-alpha by alveolar macrophages in hypersensitivity pneumonitis. 61 54
15554076 2004
8
Flow cytometric detection of cell-associated interleukin-8 in alveolar macrophages in vivo from patients with hypersensitivity pneumonitis and sarcoidosis. 54 61
15222634 2004
9
The role of interleukin-8 in interstitial pneumonia. 54 61
12856739 2003
10
Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor. 54 61
11371023 2001
11
Mushroom worker's lung caused by spores of Hypsizigus marmoreus (Bunashimeji): elevated serum surfactant protein D levels. 54 61
11083713 2000
12
ARDS after double extrinsic exposure hypersensitivity pneumonitis. 54 61
10470583 1999
13
Expression of costimulatory molecules on alveolar macrophages in hypersensitivity pneumonitis. 61 54
10351927 1999
14
Expression of C-C chemokines in bronchoalveolar lavage cells from patients with granulomatous lung diseases. 54 61
10384061 1999
15
[Significance of serum surfactant protein-D (SP-D) level in patients with pulmonary tuberculosis]. 54 61
9844346 1998
16
[Summer-type hypersensitivity pneumonitis in a patient with a positive skin test (15 minutes) for Trichosporon mucoides and a high serum IgE level]. 54 61
8953916 1996
17
Chemokines in bronchoalveolar lavage fluid in summer-type hypersensitivity pneumonitis. 54 61
7589391 1995
18
Proinflammatory cytokines in hypersensitivity pneumonitis. 54 61
7812548 1995
19
Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. 54 61
7921434 1994
20
Increased expression of the monocyte differentiation antigen CD14 in extrinsic allergic alveolitis. 54 61
7510201 1993
21
Elevated levels of bronchoalveolar lavage vitronectin in hypersensitivity pneumonitis. 61 54
7679264 1993
22
A role for IgE in extrinsic allergic alveolitis? 54 61
1387827 1992
23
Mechanisms accounting for lymphocytic alveolitis in hypersensitivity pneumonitis. 61 54
2144545 1990
24
Expression of the Fc-receptor for IgE (Fc epsilon RII, CD23) on alveolar macrophages in extrinsic allergic alveolitis. 61 54
2139100 1990
25
Comparative safety of flavocoxid vs prescription NSAIDs among osteoarthritis patients. 61
32305527 2020
26
Histology is critical but not always for the diagnosis of chronic hypersensitivity pneumonitis. 61
32265153 2020
27
Decreased expression of transmembrane TNFR2 in lung leukocytes subpopulations of patients with non-fibrotic hypersensitivity pneumonitis compared with the fibrotic disease. 61
32305453 2020
28
Progressive multifocal leukoencephalopathy in a lung transplant recipient presenting with memory impairment: Case report and literature review. 61
32291834 2020
29
Pediatric Acute Respiratory Distress Syndrome and Hypersensitivity Pneumonitis Related to E-cigarette Vaping. 61
32351768 2020
30
Identification of Autophagy-related Proteins in Lungs From Hypersensitivity Pneumonitis Patients. 61
32496163 2020
31
Antibody and T cell responses against avian and microbial antigens associate with hypersensitivity pneumonitis disease parameters in pigeon breeders. 61
31833564 2020
32
A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. 61
31958445 2020
33
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis. 61
32574666 2020
34
IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis. 61
31877269 2020
35
Age Associated B Cells Appear in Patients with Granulomatous Lung Diseases. 61
32501729 2020
36
High-resolution CT features distinguishing usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis from those with idiopathic pulmonary fibrosis. 61
32103467 2020
37
Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management. 61
32415523 2020
38
The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease. 61
32567402 2020
39
Prognostic factors in chronic hypersensitivity pneumonitis. 61
32414744 2020
40
Reply: COVID-19, A and Hypersensitivity Pneumonitis. 61
32537959 2020
41
A Pathophysiological Perspective on COVID-19's Lethal Complication: From Viremia to Hypersensitivity Pneumonitis-like Immune Dysregulation. 61
32537960 2020
42
Second-Opinion Reads in Interstitial Lung Disease Imaging: Added Value of Subspecialty Interpretation. 61
31930981 2020
43
Non-necrotizing Granulomatous Pneumonitis and Chronic Pleuritis in Soldiers Deployed to Southwest Asia. 61
32379353 2020
44
Clinical and radiological characteristics of e-cigarette or vaping product use associated lung injury. 61
32462343 2020
45
Pantoea agglomerans chronic exposure induces epithelial-mesenchymal transition in human lung epithelial cells and mice lungs. 61
32146192 2020
46
Hypersensitivity pneumonitis: Need for a better diagnostic evaluation. 61
32014420 2020
47
Hypersensitivity pneumonitis: Main features characterization in a Portuguese cohort. 61
31672592 2020
48
Republished: Sertraline-induced hypersensitivity pneumonitis. 61
32188684 2020
49
Japanese guidelines for occupational allergic diseases 2020. 61
32471740 2020
50
Acute exacerbations of fibrotic interstitial lung diseases. 61
31426125 2020

Variations for Extrinsic Allergic Alveolitis

Expression for Extrinsic Allergic Alveolitis

Search GEO for disease gene expression data for Extrinsic Allergic Alveolitis.

Pathways for Extrinsic Allergic Alveolitis

Pathways related to Extrinsic Allergic Alveolitis according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 PI3 MPO IL6 IL2RA IL1B IL15
2
Show member pathways
13.86 IL6 IL2RA IL1B IL15 IL10 CXCR3
3
Show member pathways
13.66 SOD2 IL6 IL2RA IL1B IL15 IL10
4
Show member pathways
13.58 IL6 IL2RA IL1B IL15 IL10 CXCL8
5
Show member pathways
13.45 IL6 IL2RA IL1B IL15 IL10 CXCR3
6
Show member pathways
13.34 IL6 IL2RA IL1B IL15 IL10 IGHE
7
Show member pathways
13.28 IL6 IL2RA IL1B IL15 IL10 CXCR3
8
Show member pathways
13.12 SFTPD IL6 IL1B IL10 CXCL8 CCL5
9
Show member pathways
13 IL6 IL1B CXCL8 CXCL2 CCL5 CCL3
10
Show member pathways
12.95 CXCR3 CXCL8 CXCL5 CXCL2 CCL5 CCL3
11
Show member pathways
12.89 IL6 IL2RA IL1B IL15 IL10 CXCL8
12
Show member pathways
12.89 IL6 IL2RA IL1B FCER2 CXCL8 CCL5
13 12.64 MPO IL2RA IL1B IL10 CCL5 CCL2
14
Show member pathways
12.63 MPO IL6 IL1B IL10 CCL2
15
Show member pathways
12.41 SOD2 MPO IL6 IL1B CCL5 CCL2
16
Show member pathways
12.4 IL6 IL1B CXCL8 CXCL5 CXCL2 CCL2
17
Show member pathways
12.35 IL6 IL2RA IL1B IL15 IL10 CXCL8
18 12.32 IL6 IL1B CXCL8 CXCL2 CCL5 CCL2
19
Show member pathways
12.22 SFTPD IL6 IL1B CXCL8
20 12.21 IL6 IL1B IL10 CXCL8
21
Show member pathways
12.19 IL6 IL2RA IL10 CXCR3 CXCL8 CXCL5
22 12.1 IL6 IL1B IL10 CXCL8 CCL2
23 12.1 IL6 IL1B CXCL8 CXCL2 CCL2
24 12.08 MPO IL6 IL2RA IL15 IL10
25 12 IL6 IL1B CXCL8 CCL3
26 12 IL6 IL1B IL10 CXCL8 CXCL2
27 11.97 IL6 IL1B CXCL8 CCL2
28 11.97 IL6 IL1B IL10 IGHE FCER2 CXCL8
29 11.96 IL6 IL2RA IL1B FCER2
30 11.91 IL6 IL1B IL15 CXCL5 CXCL2 CCL5
31 11.89 IL2RA IL1B IL15 IL10 CXCR3 CCL3
32 11.85 IL6 IL1B IL10 CXCL8 CXCL5
33
Show member pathways
11.76 IL6 IL1B CXCL8 CXCL2
34 11.75 IL6 IL1B IL10
35 11.7 IL6 IL1B CXCL8 CXCL2
36 11.68 IL10 IGHE FCER2
37 11.64 IL6 IL1B IL10 CXCL8 CCL2
38 11.6 IL6 IL1B CXCL8 CXCL2 CCL5 CCL3
39 11.58 IL6 IL1B IL15 CXCL8 CXCL5 CXCL2
40 11.56 MPO IL6 HP
41 11.55 IL6 IL2RA CXCL8
42
Show member pathways
11.46 IL2RA IL15 IL10 CCL3
43 11.44 IL6 IL1B IL10
44 11.41 IL6 IL1B CCL5
45 11.41 IL6 IL1B IL10
46 11.39 IL6 CXCL8 CCL2
47 11.36 IL6 IL1B IL15
48 11.36 IL6 IL1B IL15 IL10 CXCL2
49 11.06 MPO IL1B CCL3 CCL2
50 11.01 IL6 IL1B IL15 IL10 CXCL8 CXCL5

GO Terms for Extrinsic Allergic Alveolitis

Cellular components related to Extrinsic Allergic Alveolitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.83 SFTPD PI3 MPO IL6 IL1B IL15
2 extracellular region GO:0005576 9.55 SFTPD PI3 MPO IL6 IL1B IL15

Biological processes related to Extrinsic Allergic Alveolitis according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.29 IL6 IL1B IL15 IL10 CXCR3 CXCL8
2 G protein-coupled receptor signaling pathway GO:0007186 10.2 CXCR3 CXCL8 CXCL5 CXCL2 CCL5 CCL3
3 negative regulation of cell proliferation GO:0008285 10.06 SOD2 IL6 IL1B IL10 CXCL8
4 MAPK cascade GO:0000165 10.02 IL2RA IL1B CCL5 CCL3 CCL2
5 defense response to bacterium GO:0042742 10.01 SFTPD MPO IL10 IGHE HP
6 cell-cell signaling GO:0007267 10 IL1B IL15 CXCL5 CCL5 CCL3
7 positive regulation of cell migration GO:0030335 9.98 SOD2 IL1B CCL5 CCL3
8 defense response GO:0006952 9.97 MPO HP CXCL8 CXCL5 CXCL2
9 cellular response to lipopolysaccharide GO:0071222 9.95 IL6 IL1B IL10 CXCL8 CXCL5 CXCL2
10 cellular response to tumor necrosis factor GO:0071356 9.94 CXCL8 CCL5 CCL3 CCL2
11 cell chemotaxis GO:0060326 9.91 CXCR3 CXCL5 CXCL2 CCL5 CCL3 CCL2
12 chemotaxis GO:0006935 9.91 CXCR3 CXCL8 CXCL5 CXCL2 CCL5 CCL3
13 inflammatory response GO:0006954 9.9 IL6 IL2RA IL1B IL15 CXCR3 CXCL8
14 cellular response to interleukin-1 GO:0071347 9.89 CXCL8 CCL5 CCL3 CCL2
15 cellular response to organic cyclic compound GO:0071407 9.88 IL1B CCL5 CCL3 CCL2
16 positive regulation of T cell proliferation GO:0042102 9.88 IL6 IL2RA IL1B IL15 CCL5
17 calcium-mediated signaling GO:0019722 9.87 CXCR3 CXCL8 CCL3
18 neutrophil chemotaxis GO:0030593 9.87 IL1B CXCL8 CXCL5 CXCL2 CCL5 CCL3
19 cellular oxidant detoxification GO:0098869 9.85 MPO HP ALB
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IL6 IL15 CCL5
21 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.85 CXCL8 CXCL5 CXCL2
22 monocyte chemotaxis GO:0002548 9.84 IL6 CCL5 CCL3 CCL2
23 protein kinase B signaling GO:0043491 9.83 IL1B CCL5 CCL3 CCL2
24 positive regulation of phagocytosis GO:0050766 9.82 SFTPD IL1B IL15
25 negative regulation of T cell proliferation GO:0042130 9.82 SFTPD IL2RA IL10
26 lymphocyte chemotaxis GO:0048247 9.81 CCL5 CCL3 CCL2
27 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 IL1B CCL5 CCL3 CCL2
28 cellular response to fibroblast growth factor stimulus GO:0044344 9.8 CXCL8 CCL5 CCL2
29 positive regulation of JAK-STAT cascade GO:0046427 9.8 IL6 IL10 CCL5
30 leukocyte chemotaxis GO:0030595 9.8 IL10 CXCL8 CXCL5 CXCL2
31 chemokine-mediated signaling pathway GO:0070098 9.8 CXCR3 CXCL8 CXCL5 CXCL2 CCL5 CCL3
32 eosinophil chemotaxis GO:0048245 9.77 CCL5 CCL3 CCL2
33 macrophage chemotaxis GO:0048246 9.76 SFTPD CCL5 CCL3 CCL2
34 neutrophil activation GO:0042119 9.74 IL15 CXCL8 CCL5
35 response to molecule of bacterial origin GO:0002237 9.73 IL10 CXCL8 CXCL2
36 cytokine-mediated signaling pathway GO:0019221 9.7 IL6 IL2RA IL1B IL10 IGHE FCER2
37 positive regulation of neuroinflammatory response GO:0150078 9.69 IL6 IL1B
38 negative regulation by host of viral transcription GO:0043922 9.69 CCL5 CCL3
39 PERK-mediated unfolded protein response GO:0036499 9.68 CXCL8 CCL2
40 T cell chemotaxis GO:0010818 9.68 CXCR3 CCL3
41 regulation of defense response to virus by host GO:0050691 9.66 IL1B IL15
42 positive regulation of natural killer cell chemotaxis GO:2000503 9.65 CCL5 CCL3
43 astrocyte cell migration GO:0043615 9.65 CCL3 CCL2
44 immune response GO:0006955 9.44 IL6 IL2RA IL1B IL15 IL10 IGHE

Molecular functions related to Extrinsic Allergic Alveolitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.43 CCL5 CCL3 CCL2
2 chemokine activity GO:0008009 9.43 CXCL8 CXCL5 CXCL2 CCL5 CCL3 CCL2
3 CCR5 chemokine receptor binding GO:0031730 9.4 CCL5 CCL3
4 phospholipase activator activity GO:0016004 9.37 CCL5 CCL3
5 CXCR chemokine receptor binding GO:0045236 9.33 CXCL8 CXCL5 CXCL2
6 CCR1 chemokine receptor binding GO:0031726 9.32 CCL5 CCL3
7 cytokine activity GO:0005125 9.32 IL6 IL1B IL15 IL10 CXCL8 CXCL5

Sources for Extrinsic Allergic Alveolitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....